Intrapleural natural beta interferon in the treatment of malignant pleural effusions

Oncology. 1988;45(3):253-6. doi: 10.1159/000226571.

Abstract

Effusion recurrence is a major problem in the palliative care of patients with disseminated cancer. Thirty-two patients with recurrent malignant pleural effusions were treated with intracavitary natural beta-interferon at increasing doses (5-20 million units) for a maximum of three administrations. Among 29 evaluable patients, 11 showed complete (27.6%) or partial (10.3%) remission. No difference in response rate was observed according to sex, age, and histological type. All the responses were observed in patients with an effusion volume less than 1,000 ml (11/16; 68.8%). No side effect was observed. In conclusion, intrapleural beta-interferon is promising as a palliative in the treatment of recurrent malignant effusions.

MeSH terms

  • Adenocarcinoma / complications
  • Carcinoma, Non-Small-Cell Lung / complications
  • Carcinoma, Small Cell / complications
  • Drug Evaluation
  • Female
  • Humans
  • Injections
  • Interferon Type I / administration & dosage
  • Interferon Type I / therapeutic use*
  • Lung Neoplasms / complications*
  • Male
  • Mesothelioma / complications
  • Palliative Care
  • Pleura
  • Pleural Effusion / etiology
  • Pleural Effusion / therapy*
  • Recurrence

Substances

  • Interferon Type I